Compare Incyte Corporation (INCY) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs NIO Inc. — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while NIO Inc. trades at $4.55 (market cap $11.59B). The key difference: Incyte Corporation is far larger — about 2.1× NIO Inc.'s market cap, and Incyte Corporation is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals.
| INCY | NIO | |
|---|---|---|
Market Cap | $24.54B | $11.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $7.89 |
52-Week Low | $81.61 | $4.44 |
Enterprise Value | $20.04B | $10.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
NIO's stock trades at $4.555, down 5.5% in the last session amid a bearish technical signal and negative cash flow trends. The company shows revenue growth with 2025 sales reaching $87.49 billion, but remains unprofitable with a net loss of $15.57 billion. Recent news highlights delivery growth and policy support for EVs in China, yet investor sentiment is mixed due to competitive pressures and high cash burn.
The outlook is cautious; while analyst consensus leans bullish with 54% buy ratings, fundamental weaknesses in profitability and negative equity pose significant risks. Upside depends on sustained revenue expansion and cost control, but volatility from market sentiment and execution challenges warrants careful monitoring for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
